Cereno Scientific publishes annual report for 2021

Cereno Scientific (XSAT: CRNO B) today announced that the annual report for 2021 is published on the company’s website, www.cerenoscientific.com.

Cereno’s annual report for 2021 is available on the company’s website, both in Swedish and in English.

The annual general meeting (AGM) will be held in Gothenburg, Sweden, on June 1, 2022. Notice and other documents related to the AGM will be available on the company's website no later than two weeks prior.

For further information, please contact:

Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The CS585 program consists of stable, selective, and potent IP (prostacyclin) receptor agonists and the CS014 program comprises HDAC inhibitors with epigenetic effects. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.